Veronica M. Herrera

Veronica M. Herrera

Auto-generated profile, based on publicly available information

Veronica M. Herrera

Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Science Immunology
Verified
Journal Article
Closed access
MWMax M. Wattenberg
Max M. Wattenberg
HCHeather Coho
Heather Coho
VHVeronica M. Herrera
Veronica M. Herrera
KGKathleen Graham
Kathleen Graham
MSMeredith L. Stone
Meredith L. Stone
GBGregory L. Beatty
Gregory L. Beatty
Myeloid cells facilitate T cell immune evasion in cancer yet are pliable and have antitumor potential. Here, by cotargeting myeloid activation molecules, we leveraged the myeloid compartment as a therapeutic vulnerability in mouse models of pancreatic cancer. Myeloid cells in solid tumors expressed activation receptors including the pattern recognition receptor Dectin-1 and the TNF receptor superfamily member CD40. In mouse models of checkpoint inhibitor–resistant pancreatic cancer, coactivation of Dectin-1, via systemic β-glucan therapy, and CD40, with agonist antibody treatment, eradicated established tumors and induced immunological memory. Antitumor activity was dependent on cDC1s and T cells but did not require classical T cell–mediated cytotoxicity or blockade of checkpoint molecules. Rather, targeting CD40 drove T cell–mediated IFN-γ signaling, which converged with Dectin-1 activation to program distinct macrophage subsets to facilitate tumor responses. Thus, productive cancer immune surveillance in pancreatic tumors resistant to checkpoint inhibition can be invoked by coactivation of complementary myeloid signaling pathways.

8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MWMax M. Wattenberg
Max M. Wattenberg
VHVeronica M. Herrera
Veronica M. Herrera
MGMichael A. Giannone
Michael A. Giannone
WGWhitney L. Gladney
Whitney L. Gladney
ECErica L. Carpenter
Erica L. Carpenter
GBGregory L. Beatty
Gregory L. Beatty
Agonistic anti-CD40 monoclonal antibody (mAb) therapy in combination with chemotherapy (chemoimmunotherapy) shows promise for the treatment of pancreatic ductal adenocarcinoma (PDA). To gain insight into immunological mechanisms of response and resistance to chemoimmunotherapy, we analyzed blood samples from patients ( n = 22) with advanced PDA treated with an anti-CD40 mAb (CP-870,893) in combination with gemcitabine. We found a stereotyped cellular response to chemoimmunotherapy characterized by transient B cell, CD56 + CD11c + HLA-DR + CD141 + cell, and monocyte depletion and CD4 + T cell activation. However, these cellular pharmacodynamics did not associate with outcomes. In contrast, we identified an inflammatory network in the peripheral blood consisting of neutrophils, cytokines (IL-6 and IL-8), and acute phase reactants (C-reactive protein and serum amyloid A) that was associated with outcomes. Furthermore, monocytes from patients with elevated plasma IL-6 and IL-8 showed distinct transcriptional profiles, including upregulation of CCR2 and GAS6 , genes associated with regulation of leukocyte chemotaxis and response to inflammation. Patients with systemic inflammation, defined by neutrophil/lymphocyte ratio (NLR) greater than 3.1, had a shorter median overall survival (5.8 vs. 12.3 months) as compared with patients with NLR less than 3.1. Taken together, our findings identify systemic inflammation as a potential resistance mechanism to a CD40-based chemoimmunotherapy and suggest biomarkers for future studies.

17 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MSMeredith L. Stone
Meredith L. Stone
JLJesse Lee
Jesse Lee
VHVeronica M. Herrera
Veronica M. Herrera
KGKathleen Graham
Kathleen Graham
JLJae W. Lee
Jae W. Lee
GBGregory L. Beatty
Gregory L. Beatty
Agonist CD40 antibodies are under clinical development in combination with chemotherapy as an approach to prime for antitumor T cell immunity. However, treatment with anti-CD40 is commonly accompanied by both systemic cytokine release and liver transaminase elevations, which together account for the most common dose-limiting toxicities. Moreover, anti-CD40 treatment increases the potential for chemotherapy-induced hepatotoxicity. Here, we report a mechanistic link between cytokine release and hepatotoxicity induced by anti-CD40 when combined with chemotherapy and show that toxicity can be suppressed without impairing therapeutic efficacy. We demonstrate in mice and humans that anti-CD40 triggers transient hepatotoxicity marked by increased serum transaminase levels. In doing so, anti-CD40 sensitizes the liver to drug-induced toxicity. Unexpectedly, this biology is not blocked by the depletion of multiple myeloid cell subsets, including macrophages, inflammatory monocytes, and granulocytes. Transcriptional profiling of the liver after anti-CD40 revealed activation of multiple cytokine pathways including TNF and IL-6. Neutralization of TNF, but not IL-6, prevented sensitization of the liver to hepatotoxicity induced with anti-CD40 in combination with chemotherapy without impacting antitumor efficacy. Our findings reveal a clinically feasible approach to mitigate toxicity without impairing efficacy in the use of agonist CD40 antibodies for cancer immunotherapy.

8 September 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
MSMeredith L. Stone
Meredith L. Stone
VHVeronica M. Herrera
Veronica M. Herrera
YLYan Li
Yan Li
HCHeather Coho
Heather Coho
YXYuqing Xue
Yuqing Xue
GBGregory L. Beatty
Gregory L. Beatty
Pancreatic ductal adenocarcinoma (PDA) is characterized by a myeloid-enriched microenvironment and has shown remarkable resistance to immune checkpoint blockade (e.g., anti–PD-1 and anti–CTLA-4). In this study, we sought to define the role of myeloid immunosuppression in immune resistance in PDA. We report that although depletion of CSF1R+ myeloid cells in combination with anti–PD-1 and chemotherapy triggers T-cell infiltration into PDA, it also causes compensatory remodeling of the myeloid compartment with limited tumor control. Combination therapy against multiple myeloid targets, including CSF1R, CCR2/5, and CXCR2, was insufficient to overcome treatment resistance. High-dimensional single-cell analyses performed on T-cell infiltrates in human and mouse PDA revealed upregulation of multiple immune checkpoint molecules, including PD-1, LAG-3, and CTLA-4. Combinatorial blockade of PD-1, LAG-3, and CTLA-4 along with chemotherapy and anti-CSF1R was necessary to trigger activation of peripheral CD4+ and CD8+ T cells and led to deep, durable, and complete tumor responses, with each immune checkpoint blockade agent contributing to efficacy. Our findings indicate that a comprehensive approach targeting both negative regulatory signals controlling T-cell function and the myeloid compartment will be fundamental to unveiling the potential of immunotherapy in PDA.

3 November 2025
Verified
Other
Open access
PDF file
MSMeredith L. Stone
Meredith L. Stone
VHVeronica M. Herrera
Veronica M. Herrera
YLYan Li
Yan Li
HCHeather Coho
Heather Coho
YXYuqing Xue
Yuqing Xue
GBGregory L. Beatty
Gregory L. Beatty
T cell activation in the peripheral blood is improved when immune checkpoint blockade is combined with chemotherapy and CSF1R+ cell ablation

3 November 2025
Verified
Other
Open access
PDF file
MSMeredith L. Stone
Meredith L. Stone
VHVeronica M. Herrera
Veronica M. Herrera
YLYan Li
Yan Li
HCHeather Coho
Heather Coho
YXYuqing Xue
Yuqing Xue
GBGregory L. Beatty
Gregory L. Beatty
Heterogeneous myeloid populations within the murine PDA microenvironment express potential therapeutic targets